Compare BOSC & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BOSC | XCUR |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.7M | 26.6M |
| IPO Year | 2002 | 2017 |
| Metric | BOSC | XCUR |
|---|---|---|
| Price | $4.76 | $3.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 56.9K | 8.5K |
| Earning Date | 05-28-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.52 | $3.10 |
| 52 Week High | $6.72 | $11.60 |
| Indicator | BOSC | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | 52.13 | 32.16 |
| Support Level | $4.64 | $3.10 |
| Resistance Level | $5.07 | $4.23 |
| Average True Range (ATR) | 0.14 | 0.16 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 84.50 | 16.67 |
BOS Better Online Solutions Ltd is a provider of Intelligent Robotics and Supply Chain solutions for enterprises. The company manages its business in three reportable divisions: the Intelligent Robotics segment, the RFID Division segment, and the Supply Chain Solutions segment. The majority of revenue derives from Supply Chain Solutions which distributes electro-mechanical components, mainly to customers in the aerospace, defense, and other industries, and is a supply chain service provider for aviation customers that seek a comprehensive solution to their components-supply needs. Geographically company derives the majority of its revenue from Israel.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.